G1 Therapeutics to Participate in the H.C. Wainwright & Co. Global Investment Conference

Rhea-AI Summary

G1 Therapeutics (GTHX) announced its CEO, Jack Bailey, will present at the H.C. Wainwright & Co. Global Investment Conference, with a virtual presentation scheduled for May 24, 2022, at 7:00 AM EDT. This event will be accessible both in-person and online. G1 Therapeutics focuses on developing next-generation oncology therapies, including its first commercial product, COSELA™ (trilaciclib). The company has a robust clinical pipeline targeting various solid tumors, such as colorectal, breast, lung, and bladder cancers.

RESEARCH TRIANGLE PARK, N.C., May 18, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that Jack Bailey, G1’s Chief Executive Officer, will provide a virtual corporate presentation during the H.C. Wainwright & Co. Global Investment Conference. The presentation will become available at 7:00 AM EDT on May 24, 2022. This meeting is being held in person and virtually; the webcast of G1’s presentation will be accessible on the Events & Presentations page of http://www.g1therapeutics.com.

About G1 Therapeutics
G1 Therapeutics, Inc. is a commercial-stage oncology company focused on the development and commercialization of next generation therapies that improve the lives of those affected by cancer, including the Company’s first commercial product, COSELA™ (trilaciclib). G1 has a deep clinical pipeline and is executing a tumor-agnostic development plan evaluating COSELA in a variety of solid tumors, including colorectal, breast, lung, and bladder cancers. G1 Therapeutics is based in Research Triangle Park, N.C. For additional information, please visit www.g1therapeutics.com and follow us on Twitter @G1Therapeutics.

Contacts:
Will Roberts
Vice President, Investor Relations & Corporate Communications
919-907-1944
wroberts@g1therapeutics.com

FAQ

What is the date and time of G1 Therapeutics' presentation at the H.C. Wainwright & Co. Global Investment Conference?

G1 Therapeutics' presentation will take place on May 24, 2022, at 7:00 AM EDT.

Who will present on behalf of G1 Therapeutics at the conference?

Jack Bailey, the CEO of G1 Therapeutics, will present at the conference.

Where can I access the webcast of G1 Therapeutics' presentation?

The webcast will be available on G1 Therapeutics' Events & Presentations page on their official website.

What is COSELA and why is it significant for G1 Therapeutics?

COSELA™ (trilaciclib) is G1 Therapeutics' first commercial product, aimed at improving outcomes for cancer patients.

What types of cancers is G1 Therapeutics targeting with its clinical pipeline?

G1 Therapeutics is focusing on solid tumors, including colorectal, breast, lung, and bladder cancers.